Nian Gen Sheng Wu Kexue Gongsi 2025 Nian Du Quji Baogao

NIAGEN BIOSCIENCE, INC. Niagen Bioscience, Inc.Quarterly Report on Form 10-QFor the Three Months Ended March31, 2025 PART I - Financial Information (unaudited) Item 1. Financial Statements (unaudited):3Condensed Consolidated Balance Sheets as ofMarch31, 2025andDecember31, 20243Condensed Consolidated Statements of Operations for thethreemonths endedMarch31, 2025andMarch31, 20244Condensed Consolidated Statements of Stockholders’ Equity for thethreemonths endedMarch31, 2025andMarch31,20245 PART II - Other Information Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 5. Other information Niagen Bioscience, Inc. and SubsidiariesUnaudited Condensed Consolidated Balance Sheets(In thousands except par values, unless otherwise indicated) Niagen Bioscience, Inc. and SubsidiariesUnaudited Condensed Consolidated Statements of Operations(In thousands, except per share data) Niagen Bioscience, Inc. and SubsidiariesUnaudited Condensed Consolidated Statements of Stockholders' Equity Note 1.Nature of Business Niagen Bioscience, Inc. (formerly ChromaDex Corporation) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDexInternational, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Asia PacificVentures Limited, ChromaDex Europa B.V., ChromaDex Trading (Shanghai) Co., Ltd. and ChromaDex Sağlik Ürünleri AnonimŞirketi (collectively, “Niagen Bioscience” or the “Company”) are a global bioscience company dedicated to healthy aging. The NiagenBioscience team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), anessential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in Niagen Bioscience is the innovator behind the NAD+ precursor nicotinamide riboside chloride (“NRC”, commonly referred to as“NR”), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide ribosidechloride and other NAD+ precursors are protected by Niagen Bioscience’s patent and/or licensed rights portfolio. The Companydelivers food-grade Niagen® as the sole or principal dietary ingredient in its dietary supplement consumer product line, Tru Niagen®.As part of its consumer product offerings, the Company offers NAD+ test kits exclusively to healthcare practitioners. Furthermore, theCompany develops and commercializes proprietary ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Note 2.Basis of Presentation and Significant Accounting Policies Basis of Presentation:The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordancewith accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or“GAAP”) for interim financial information and the instructions to Form 10-Q and Regulation S-X promulgated under the SecuritiesExchange Act of 1934, as amended (the “Exchange Act”). Certain information and footnote disclosures normally included in financialstatements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinionof management, the interim Unaudited Condensed Consolidated Financial Statements include all adjustments, including normal Basis of Consolidation:The accompanying Unaudited Condensed Financial Statements and notes thereto have been prepared on aconsolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant Significant Accounting Policies:There have been no changes to the Company’s significant accounting policies described in theCompany’s 2024 Annual Report on Form 10-K that have had a material impact on the Company’s Unaudited Condensed Consolidated Accounting Standards Recently Issued but Not Yet Adopted by the Company: In October 2023, the FASB issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to the SEC’sDisclosure Update and Simplification Initiative,” to amend certain disclosure and presentation requirements for a variety of topicswithin the Accounting Standards Codification (ASC). These amendments align the requirements in the ASC to the removal of certaindisclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amendedtopic in the ASC is either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." ASU2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxespaid information. A public entity should apply the